Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02779608
Other study ID # Ifen
Secondary ID
Status Recruiting
Phase Phase 2
First received May 15, 2016
Last updated January 23, 2017
Start date January 20, 2017
Est. completion date June 2018

Study information

Verified date January 2017
Source Fudan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a clinical Study to evaluate the effect, survival benefit and safety of intraperitoneal docetaxel combined with oral S-1 for advanced gastric cancer with malignant ascites.


Description:

Peritoneal metastasis(PM) is common in advanced gastric cancer and associated with a poor prognosis. The median survival time is 3 to 4 months and even shorter in the patients with malignant ascites. Systemic chemotherapy is considered to be less effective against peritoneal metastasis (PM) due to the existence of the blood-peritoneal barrier (BPB), which inhibits the movement of drugs from systemic circulation to the peritoneal cavity.

S-1 is one kind of oral fluoropyrimidine derivatives and has been reported to be effective on PM. Docetaxel (DTX) has a pharmacokinetic advantage after intraperitoneal(IP)delivery which is hundreds of times higher than systemic administration. The use of S-1 and docetaxel has been studied in some phase II trials. Fujiwara and Fushida reported the usefulness of IP docetaxel combined with oral S-1 regimen in gastric cancer with PM respectively,the median survival time can exceed 16 months and one year survival rate was over 70%. Therefore, the investigators suppose IP docetaxel and oral S-1 can also be effective for gastric cancer with malignant ascites and start this study.

This is a single center, open-label, prospective clinical trial. Patients with histological proven gastric cancer with ascites, who fulfill the inclusion and exclusion criteria, can be recruited in this study. Patients will be firstly received laparoscopic exploration for Peritoneal Cancer Index (PCI)score, extraction of 100ml ascites for cytology examination, and one peritoneal access port is implanted in the subcutaneous space of the lower abdomen. Then patients were treated with chemotherapy on the first day after operation, the regimen as follows: DTX is administered IP at a dose of 60 mg/m2 on day 1. DTX is diluted in 1 litre normal saline and administered through the implanted peritoneal access port over 1 hour. S-1 was administered orally twice daily at a dose of 80 mg/m2 per day for 14 consecutive days, followed by 7 days of rest. The treatment course will be repeated every three weeks until observation of disease progression or unacceptable toxicity. Before each intraperitoneal chemotherapy, investigators extract 50-100 ml ascites for cytology pathologic examination, the abdominal CT will be reviewed after every three course to evaluate the volume of ascites.

The volume of ascites before and after therapy, PCI scores, ascites cytology results, complications, side effects and conditions of survival state and follow-up will be recorded and analyzed to evaluate the effect, survival benefit and safety of this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 2018
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria:

1. Age 20-75years

2. Histologic confirmation of gastric adenocarcinoma

3. Positive peritoneal cytology or histological proven PM

4. Ascites in CT scan

5. Performance status (PS) = 2 on Eastern Cooperative Oncology Group (ECOG) scale

6. Adequate bone marrow and organ functions as defined below:

Leucocyte=3,000/ul Absolute neutrophil counts =1,500/uL Platelet=100,000/uL Total bilirubin=1.5mg/dl ALT,AST= 2x ULN serum creatinine =1.5mg/dl

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

8. Provision of written informed consent

Exclusion Criteria:

1. Presence of non-curable factors such as distant metastasis to liver or lung except of peritoneum

2. Other severe medical conditions such as symptomatic infectious disease,active hemorrhage/bleeding, or obstructive bowel disease

3. Life expectation = 3 months

4. With other malignant tumor

5. allergy to therapeutic drugs

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
intraperitoneal docetaxel
One peritoneal access port will be implanted in subcutaneous space of patients' abdominal wall after laparoscopic exploration.Then intraperitoneal docetaxel in 1litre normal saline will be administered through the port
oral S-1
40mg/m² twice daily on day 1-14 every 3 weeks

Locations

Country Name City State
China Huashan Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary response rate of ascites From date of enrollment to three cycles of treatment,the ascites is evaluated by the Japanese conventional five-point method 9 weeks
Secondary one year survival rate From date of enrollment until 1 year 1 year
Secondary side effects of chemotherapy Grade refers to Common Terminology Criteria for Adverse Events(CTCAE)Version4.0 1 week to 18 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT04351867 - A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer Phase 3
Recruiting NCT02887612 - ctDNA for Prediction of Relapse in Gastric Cancer
Active, not recruiting NCT02930291 - The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic Gastrectomy
Completed NCT02649348 - Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome N/A
Recruiting NCT02310230 - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy N/A
Active, not recruiting NCT01609309 - Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01) Phase 3
Completed NCT00375999 - Docetaxel and Epirubicin in Advanced Gastric Cancer Phase 2
Completed NCT00382720 - Docetaxel and Oxaliplatin in Gastric Cancer Phase 2
Completed NCT00980382 - A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma Phase 1/Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Recruiting NCT05033392 - PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer Phase 2
Completed NCT04539769 - Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes Phase 2
Active, not recruiting NCT02930278 - The Effect of Preoperative Hemotologic Markers on Postoperative Long-term and Short-term Outcomes for Laparoscopic Gastrectomy
Active, not recruiting NCT02845986 - Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer Phase 2
Completed NCT02902575 - The Safety and Feasibility of Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer After Neoadjuvant Chemotherapy N/A
Recruiting NCT04222114 - Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis Phase 3
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4